Gene therapy market seen hitting $46.5 billion by 2030

Allied Market Research projects the global gene therapy market will grow from $6.0 billion in 2020 to $46.5 billion by 2030, a 22.8% compound annual rate. The report points to rising chronic disease rates, government support and broader acceptance of cancer gene therapy as key growth drivers.

Why it matters: - Gene therapy is moving from a niche treatment area toward a much larger commercial market. - The market forecast signals rising demand across cancer, chronic disease, infectious disease and blood disorder treatments. - The projected expansion could influence investment, R&D priorities and healthcare access over the rest of the decade.

What happened: - Allied Market Research said the global gene therapy market was valued at $6.0 billion in 2020 and is projected to reach $46.5 billion by 2030. - The firm forecast a 22.8% compound annual growth rate from 2021 to 2030. - The report examined market size, investment opportunities, competitive dynamics, drivers, restraints and trends. - The study also highlighted top players including Gilead Sciences, Orchard Therapeutics, Bristol-Myers Squibb, Adverum Biotechnologies, Amgen, Jazz Pharmaceuticals, Shenzhen SiBiono Genentech, Adaptimmune, Novartis and Shanghai Sunway Biotech. - Sample report and purchase inquiry links were provided by Allied Market Research.

The details: - Chronic disorder prevalence, government support and ethical acceptance of gene therapy for cancer are the main growth drivers cited in the report. - High treatment cost remains a restraint on market growth. - Advanced healthcare infrastructure is expected to create additional opportunities. - By gene type, the antigen segment held nearly one-fourth of the global market in 2020. - The deficiency segment is projected to grow the fastest at 26.0% CAGR from 2021 to 2030. - By application, oncological disorders held more than two-fifths of the market in 2020. - The oncological disorders segment is also projected to post the fastest growth at 23.5% CAGR through 2030. - North America held nearly half of global revenue in 2020. - Asia-Pacific is projected to grow the fastest at 25.4% CAGR from 2021 to 2030. - The report tied Asia-Pacific growth to higher chronic disease prevalence, rising healthcare spending, infrastructure upgrades, reimbursements and major market players in the region. - The regional outlook also covered Europe and LAMEA, including Brazil, Saudi Arabia and South Africa.

Between the lines: - The report points to a market that is still constrained by cost, but supported by stronger policy, clinical adoption and infrastructure. - Oncology remains the clearest near-term commercial anchor for gene therapy products. - Fast-growth projections for Asia-Pacific suggest the market may broaden beyond its current North America-heavy revenue base. - The emphasis on top investment pockets and winning strategies suggests the report is aimed at investors and companies looking for entry or expansion points.

What’s next: - Market participants are likely to focus on lower-cost development, broader reimbursement and region-specific expansion. - Companies operating in oncology and Asia-Pacific may see the strongest near-term growth opportunities. - Further product launches and R&D spending are likely to track the disease areas and regions highlighted in the report.

The bottom line: - Allied Market Research sees gene therapy entering a high-growth phase, with cancer treatment, North American leadership and Asia-Pacific expansion shaping the market through 2030.